United States Healthcare Equipment & Supplies

Renalytix PLC (RENX)

Track

Track

Ticker: RENX Exchange: LSE
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Renalytix PLC. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
3.3
James McCullough Chief Executive Officer Officer
Transaction date
Purchase
Price
453.60
Quantity 49,849
Value US$1,218,538
Joel Jung interim Chief Financial Officer Officer
Transaction date
Purchase
Price
193.86
Quantity 76,805
Value US$2,816,130
Joel Jung interim Chief Financial Officer Officer
Transaction date
Purchase
Price
300.43
Quantity 63,142
Value US$1,845,766
3.3
James McCullough Chief Executive Officer Officer
Transaction date
Purchase
Price
3.01
Quantity 3,010
Value US$9,072
Fergus Fleming Chief Technology Officer & Executive Director Executive Director
Transaction date
Purchase
Price
0.10
Quantity 25,000
Value £2,438
3.2
Julain Baines Executive Chairman Director
Transaction date
Purchase
Price
0.09
Quantity 23,000
Value £1,955
Howard Doran President of Renalytix
Transaction date
Purchase
Price
0.09
Quantity 50,000
Value £4,450
3.3
James McCullough CEO Officer
Transaction date
Purchase
Price
0.09
Quantity 25,000
Value £2,125
Howard Doran President
Transaction date
Purchase
Price
0.08
Quantity 50,000
Value £4,000
Christopher Mills Non-Executive Chairman, Chief Investment Officer Executive Director
Through Harwood Capital LLP, a closely affiliated person
Transaction date
Purchase
Price
0.07
Quantity 48,601
Value £3,402
3.3
James McCullough Chief Executive Officer Officer
Transaction date
Purchase
Price
0.08
Quantity 53,300
Value £3,998
3.2
Julian Baines Executive Chairman Director
Transaction date
Purchase
Price
0.07
Quantity 23,989
Value £1,739
Christopher Mills Non-Executive Chairman, Chief Investment Officer Executive Director
Through Harwood Capital LLP, a closely affiliated person
Transaction date
Purchase
Price
0.09
Quantity 500,000
Value £45,000
Christopher Mills Non-Executive Chairman, Chief Investment Officer Executive Director
Through Harwood Capital LLP, a closely affiliated person
Transaction date
Sale
Price
0.08
Quantity 83,696
Value £6,696
Christopher Mills Non-Executive Chairman Executive Director
Through Harwood Capital LLP, a closely affiliated person
Transaction date
Purchase
Price
0.90
Quantity 346,375
Value £311,738
Christopher Mills Chief Executive Officer Executive Director
Through Harwood Capital LLP and Harwood Capital Management (Gibraltar) Limited, a closely affiliated person
Transaction date
Sale
Price
11.25
Quantity 6,100
Value £68,625
Fergus Fleming Chief Technology Officer Officer
Transaction date
Sale
Price
10.75
Quantity 15,000
Value £161,250
Christopher Mills non-exec director and Interim Chair Executive Director
Through Harwood Capital LLP and Harwood Capital Management (Gibraltar) Limited, a closely affiliated person
Transaction date
Sale
Price
11.35
Quantity 17,000
Value £193,000
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-02-13 2026-02-12 B Purchase
3.3
James McCullough

Chief Executive Officer

Officer
49,849
453.60
US$1,218,538 		49,849 453.60 US$1,218,538
2026-02-13 2026-02-11 B Purchase
Joel Jung

interim Chief Financial Officer

Officer
76,805
193.86
US$2,816,130 		76,805 193.86 US$2,816,130
2026-02-12 2026-02-11 B Purchase
Joel Jung

interim Chief Financial Officer

Officer
63,142
300.43
US$1,845,766 		63,142 300.43 US$1,845,766
2026-02-12 2026-02-11 B Purchase
3.3
James McCullough

Chief Executive Officer

Officer
3,010
3.01
US$9,072 		3,010 3.01 US$9,072
2024-12-20 2024-12-20 B Purchase Fergus Fleming

Chief Technology Officer & Executive Director

Executive Director
25,000
0.10
£2,438 		25,000 0.10 £2,438
2024-12-11 2024-12-10 B Purchase
3.2
Julain Baines

Executive Chairman

Director
23,000
0.09
£1,955 		23,000 0.09 £1,955
2024-12-11 2024-12-10 B Purchase Howard Doran

President of Renalytix
50,000
0.09
£4,450 		50,000 0.09 £4,450
2024-12-11 2024-12-10 B Purchase
3.3
James McCullough

CEO

Officer
25,000
0.09
£2,125 		25,000 0.09 £2,125
2024-12-09 2024-12-09 B Purchase Howard Doran

President
50,000
0.08
£4,000 		50,000 0.08 £4,000
2024-12-11 2024-12-05 B Purchase Christopher Mills

Non-Executive Chairman, Chief Investment Officer

Through Harwood Capital LLP, a closely affiliated person Executive Director
48,601
0.07
£3,402 		48,601 0.07 £3,402
2024-12-06 2024-12-05 B Purchase
3.3
James McCullough

Chief Executive Officer

Officer
53,300
0.08
£3,998 		53,300 0.08 £3,998
2024-12-04 2024-12-04 B Purchase
3.2
Julian Baines

Executive Chairman

Director
23,989
0.07
£1,739 		23,989 0.07 £1,739
2024-10-11 2024-10-08 B Purchase Christopher Mills

Non-Executive Chairman, Chief Investment Officer

Through Harwood Capital LLP, a closely affiliated person Executive Director
500,000
0.09
£45,000 		500,000 0.09 £45,000
2024-10-11 2024-10-07 S Sale Christopher Mills

Non-Executive Chairman, Chief Investment Officer

Through Harwood Capital LLP, a closely affiliated person Executive Director
83,696
0.08
£6,696 		83,696 0.08 £6,696
2023-02-10 2023-02-08 B Purchase Christopher Mills

Non-Executive Chairman

Through Harwood Capital LLP, a closely affiliated person Executive Director
346,375
0.90
£311,738 		346,375 0.90 £311,738
2021-06-28 2021-06-25 S Sale Christopher Mills

Chief Executive Officer

Through Harwood Capital LLP and Harwood Capital Management (Gibraltar) Limited, a closely affiliated person Executive Director
6,100
11.25
£68,625 		6,100 11.25 £68,625
2021-06-25 2021-06-25 S Sale Fergus Fleming

Chief Technology Officer

Officer
15,000
10.75
£161,250 		15,000 10.75 £161,250
2021-06-22 2021-06-18 S Sale Christopher Mills

non-exec director and Interim Chair

Through Harwood Capital LLP and Harwood Capital Management (Gibraltar) Limited, a closely affiliated person Executive Director
17,000
11.35
£193,000 		17,000 11.35 £193,000
Explore more

More insider trading research around Renalytix PLC

More insider trades in United States
Similar Healthcare companies with insider activity
More Healthcare Services companies with insider activity
More Healthcare Equipment & Supplies companies with insider activity
Insider trading in North America